Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the effect of mild, moderate and severe hepatic
impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral
administration of BI 10773 as a single dose.